Last reviewed · How we verify
Sofosbuvir/Ledipasvir 12W
Sofosbuvir/Ledipasvir 12W is a combination of a nucleotide analog inhibitor of the hepatitis C virus NS5B polymerase and a potent inhibitor of the hepatitis C virus NS5A protein.
Sofosbuvir/Ledipasvir 12W is a combination of a nucleotide analog inhibitor of the hepatitis C virus NS5B polymerase and a potent inhibitor of the hepatitis C virus NS5A protein. Used for Chronic hepatitis C virus infection.
At a glance
| Generic name | Sofosbuvir/Ledipasvir 12W |
|---|---|
| Sponsor | Iran Hepatitis Network |
| Drug class | NS5A inhibitor and NS5B polymerase inhibitor |
| Target | NS5A protein and NS5B polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Sofosbuvir works by inhibiting the NS5B polymerase enzyme, which is essential for the replication of the hepatitis C virus. Ledipasvir targets the NS5A protein, which plays a critical role in the viral life cycle. By inhibiting these two proteins, Sofosbuvir/Ledipasvir 12W prevents the replication of the hepatitis C virus.
Approved indications
- Chronic hepatitis C virus infection
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sofosbuvir/Ledipasvir 12W CI brief — competitive landscape report
- Sofosbuvir/Ledipasvir 12W updates RSS · CI watch RSS
- Iran Hepatitis Network portfolio CI